Evaluation and treatment of chronic renal failure.
Chronic renal failure (CRF) is the irreversible deterioration of renal function that gradually progresses to end stage renal disease (ESRD). The chief causes of CRF include obstructive uropathy, primary glomerular diseases, reflux nephropathy and hypoplastic or dysplastic kidneys. Progressive hyperperfusion and hyperfiltration causes increasing glomerular injury and further renal damage. Symptoms of CRF are usually seen when GFR is between 10-25% of normal. Children with severe CRF often suffer from failure to thrive, growth retardation, acidosis, anemia and renal osteodystrophy. Management of CRF aims at retarding progression of renal damage and treatment of complications related to renal dysfunction. Measures suggested to retard progression include protein restriction, strict control of hypertension, use of angiotensin converting enzyme inhibitors and control of hyperlipidemia. Appropriate amounts of protein and calories are recommended to prevent growth failure. Nutritional supplements are often required. The availability of recombinant erythropoietin, calcitriol and human growth hormone has significantly improved the management of these patients. Once ESRD supervenes, renal replacement therapy in the form of chronic peritoneal or hemodialysis and transplantation is necessary.
Moudgil
A
A
Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Asha.Moudgil@cshs.org
Bagga
A
A
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002648:Child; D019587:Dietary Supplements; D004921:Erythropoietin / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000379:methods
D000959:Antihypertensive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin